Week in Business: Businesses flee high-tax Britain September 11, 2025 On the same day that Reeves said "there's no growth without investment", a pharma giant pulled its £1bn London investment plans.
Merck warns UK is ‘not internationally competitive’ as it scraps £1bn London research centre September 10, 2025 Merck has pulled out of a planned £1bn London drug research centre in the latest blow to the government’s growth agenda. The US pharma giant is to lay off 127 staff alongside abandoning the construction project, which had been set to open in King’s Cross in 2027. The firm warned the UK would lag behind [...]
Trump tariffs: FTSE 100 holds steady as pharma and metals brace for levies July 9, 2025 The FTSE 100 opened 22 points up this morning, despite threats of pharma and metals tariffs with stark implications for major stocks on the blue chip index. President Trump has said that an announcement is coming “very soon” on pharmaceutical tariffs – with a possible 200 per cent rate landing in “about a year”. Major [...]
Astrazeneca chief ‘wants to shift London listing to US’ July 1, 2025 The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock market listing to the United States. Sir Pascal Soriot, who has been at the helm of the pharma juggernaut since 2012, is said to have spoken privately about his desire to abandon the UK listing in favour [...]
Invidior: Drug maker ditches London for US June 2, 2025 The London Stock Exchange suffered another blow on Monday after drug maker Invidior said it intends to abandon its London listing and focus on its primary listing in the US. The firm said it had reviewed its listing structure and considered liquidity, the location of shareholders and red tape associated with its London listing. Its [...]
GSK and Astrazeneca shares slump as Trump vows drug price cut May 12, 2025 GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.
FTSE 100’s record run ends as pharma stocks slide on new Trump appointment May 7, 2025 The FTSE 100’s record run came to an end on Wednesday as pharma stocks slumped on the back of a controversial US regulatory appointment. The blue-chip index spent the entire session in the red and closed off 0.4 per cent. Drugmakers GSK and Astrazeneca were among the top fallers, at nearly five per cent and [...]
GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs April 30, 2025 British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]
As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers? April 22, 2025 For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks. The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]
Starmer must act now to protect NHS from Trump pharma tariffs April 17, 2025 Starmer must make a deal to avoid Trump's pharma tariffs or risk a major hit to the NHS, write Ben Ramanauskas and Sean Phillips.